Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

The Non-Linear Path of Discovery, & Publicly Funded Research

Philip Seo, MD, MHS  |  Issue: November 2018  |  November 19, 2018

  1. There was no Nobel Foundation, so the money had been left to no one, to nothing;
  2. The will was imprecise, and it was not determined even in what country the will should be probated;
  3. Some of the family, who were left only a small fraction of the estate, contested the will;
  4. The press and others criticized the will, calling it unpatriotic, because it did not single out Swedes for the prize. They also argued that it should not be used to make a few individuals wealthy and voiced other objections;
  5. The assets of the estate were not liquid, and in fact were in risky ventures;
  6. The institutions chosen to award the prizes weren’t willing to accept the responsibility.”7

In addition to all of these issues, Ragnar Sohlman and Rudolf Lilljequist, the executors of Mr. Nobel’s will, had to figure out how to liquidate and transfer Mr. Nobel’s wealth from France, where he had lived, back to Sweden, before the French government could tax the proceeds. It was their efforts, over three years, which led to the realization of the Nobel Foundation and the Nobel Prize.8

Meandering Toward Greatness

By now, it is probably obvious to you why this story is relevant to us. On Oct. 1, the 2018 Nobel Prize in Physiology or Medicine was awarded to James P. Allison, PhD, of the United States and to Tasuku Honjo, MD, PhD, of Japan for their work on cancer immunotherapy.9

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Dr. Allison coined the phrase checkpoint inhibitor to describe the function of CTLA-4 on downregulating T cell function. Dr. Honjo discovered a second checkpoint, called PD-1, which is the target of nivolumab and pembrolizumab. Many forms of cancer make proteins that bind to PD-1 or CTLA-4, which prevents the malignancy from activating an immune response. By inhibiting the checkpoints, these biologic agents prevent the malignancy from inactivating T cells, leaving them free to attack.

This approach has led to a revolution in the treatment of cancer, and many patients who have malignancies previously deemed incurable have been given a reprieve by the advent of the immune checkpoint inhibitors.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

But that isn’t the story I want to tell, either.

The immune checkpoint inhibitor story is well known to us, from sources ranging from the New England Journal of Medicine to The New York Times. We are involved because it turns out that malignancy and autoimmunity may be two sides of the same coin, and by abolishing one, we may induce the other.10 The story is worth telling, and indeed, has been told in the pages of this publication, and I might write more about this fascinating field at some point in the future. But not today.

Today, I want to tell you about the Nobel Prize in Chemistry, which was awarded on Oct. 3, 2018, to Frances H. Arnold, PhD, of the California institute of Technology, George P. Smith, PhD, of the University of Missouri, and Sir Gregory P. Winter of the MRC Laboratory of Molecular Biology in England, for developing the field of synthetic biology.11

Synthetic biology is the intersection of molecular biology and engineering, which involves multiple fields, including computer science, biophysics and nanotechnology. The goal of synthetic biology is to learn how to redesign biologic systems to achieve a particular purpose.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:OpinionRheuminationsSpeak Out Rheum Tagged with:Research Funding

Related Articles

    Tear Down That Wall: CME restrictions stifle speeches

    August 1, 2010

    The Nobel Peace Prize is one of the most prestigious awards in the world because it recognizes individuals and organizations that promote the causes of peace and human rights. In 1991, Aung San Suu Kyi received this prize for her courageous work in advancing democracy in the Republic of Myanmar. Because of her leadership of the democracy movement in Myanmar, the military regime that governs that country has gone to great lengths to gag her. Indeed, she has been under house arrest for most of the last two decades since she received the Peace Prize. An outpouring of support for Aung San Suu Kyi and demands for her freedom by human rights advocates and Western governments have sadly been to no avail.

    Trio Wins Chemistry Nobel for Work on Antibody Drugs & Detergents

    October 4, 2018

    STOCKHOLM/LONDON (Reuters)—Two Americans and a Briton won the 2018 Nobel Prize for Chemistry on Wednesday for harnessing the power of evolution to generate novel proteins used in everything from environmentally friendly detergents and biofuels to cancer drugs. The fruits of this work include the world’s top-selling prescription medicine – the antibody injection Humira sold by…

    CHARAN RATTANASUPPHASIRI/shutterstock.com

    Funding Sources for Scientific Discovery, Medical Research

    March 20, 2017

    The Phone Call A phone call in the middle of the night can rattle one’s nerves. The rush of adrenaline sets the heart pounding as our ears brace for what we are about to hear next. A distress call from an elderly parent or a child away at college? Is everyone safe? Or may this…

    Recent Awards & Appointments in Rheumatology

    August 16, 2019

    Prestigious Carol Nachman Prize for Research in Rheumatology Awarded to Ellen Gravallese On May 10, Ellen M. Gravallese, MD, the Myles J. McDonough Chair in Rheumatology and chief of the Division of Rheumatology at University of Massachusetts Medical School, Worcester, was awarded the prestigious Carol Nachman Prize for lifetime achievement in rheumatology research in Wiesbaden,…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences